DMC Appoints Kelly Smith as Vice President R&D

15.03.2022 - US biobased chemical company DMC Biotechnologies has appointed Kelly Smith as Vice President R&D. Previously, she was head of bioprocessing and formulation development at Joyn Bio.

Smith has more than 20 years of experience building and leading research and development teams and has a Ph.D in Applied Microbiology from California Institute of Technology.

Matt Lipscomb, CEO & co-counder of DMC said: “Kelly has exceptional leadership qualities with a track record of building engaged, high-trust and high-results teams. As we expand our operations at DMC, we are excited to welcome Kelly to the team.”

DMC's technology platform addresses key constraints for the biotech industry, such as standardization, robustness, and predictability at large scale. Addressing these challenges, says DMC, translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.